文献速递白血病

吉瑞替尼在复发/难治性FLT3突变急性髓系白血病二线以上治疗中的有效性:171例患者真实世界多中心研究

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.
PubMed 文献 · Am J Hematol · 2025-11-22

多中心回顾性研究纳入171例在2017年8月至2024年3月间接受吉瑞替尼三线及以上治疗的复发/难治性FLT3突变急性髓系白血病成人患者,复合完全缓解率28%,总缓解率47%,中位总生存7.1个月(95%CI 5.9-10.1),12%患者得以接受造血干细胞移植。

要点

  • 吉瑞替尼三线及以上治疗复发/难治性FLT3突变急性髓系白血病,复合完全缓解率28%,总缓解率47%。
  • 中位总生存7.1个月(95%CI 5.9-10.1),缓解者及接受造血干细胞移植者生存显著改善。
  • 既往维奈克拉暴露与较差缓解和较短生存相关(5.7个月;95%CI 5.1-8.8)。

核心结论

  • 尽管经过重度预处理,吉瑞替尼在晚期复发/难治性FLT3突变急性髓系白血病中仍保留临床相关活性。
  • 吉瑞替尼二线以上使用可能作为部分患者桥接造血干细胞移植的手段。
  • 耐药机制尤其是维奈克拉暴露后的耐药仍是治疗挑战,这些数据支持继续在二线以上使用吉瑞替尼并强调需前瞻性研究优化序贯策略。

研究设计与样本

  • 多中心回顾性研究,纳入171例成人复发/难治性FLT3突变急性髓系白血病患者,接受吉瑞替尼作为三线或以上治疗。
  • 研究时间范围为2017年8月至2024年3月,中心位于意大利、西班牙、英国和土耳其。
  • 主要终点为总生存,次要终点包括总缓解率、复合完全缓解和缓解持续时间。

主要发现

  • 171例患者中84%携带FLT3-ITD突变,26%接受过≥3线既往治疗。
  • 复合完全缓解率为28%,总缓解率为47%。
  • 较年轻和复发(相对于难治)疾病患者结局更好;既往维奈克拉暴露或异基因造血干细胞移植与较差缓解相关。
  • 吉瑞替尼使12%的患者得以接受造血干细胞移植。
  • 中位总生存为7.1个月(95%CI 5.9-10.1);Cox回归分析中,缓解者和接受造血干细胞移植者总生存显著改善(中位总生存21.5个月;95%CI 12.8-NR);既往维奈克拉暴露与较短生存相关(5.7个月;95%CI 5.1-8.8);多变量分析中既往维奈克拉和FLT3抑制剂暴露是缓解率降低的最强预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3-mutated AML who received gilteritinib as third-line or beyond between August 2017 and March 2024 across centers in Italy, Spain, the United Kingdom, and Turkey. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), composite complete remission (cCR), duration of response. Among the 171 patients, 84% carried FLT3-ITD mutations and 26% had received ≥ 3 prior lines of therapy. The cCR rate was 28%, and ORR was 47%. Patients who were younger and presented with relapsed (vs. refractory) disease had better outcomes. Prior exposure to venetoclax or allogeneic hematopoietic stem cell transplantation (HSCT) was associated with inferior response. Gilteritinib enabled HSCT in 12% of patients. Median OS was 7.1 months (95% CI, 5.9-10.1), and in Cox-regression analysis was significantly improved among responders and those who underwent HSCT (median OS: 21.5 months; 95% CI, 12.8-NR). Prior venetoclax exposure was associated with shorter survival (5.7 months; 95% CI, 5.1-8.8). On multivariate analysis, previous exposure to venetoclax and FLT3 inhibitors was the strongest predictor of reduced response rates. Despite heavy pretreatment, gilteritinib retained clinically relevant activity in later-line R/R FLT3-mutated AML. Its use beyond second-line may serve as a bridge to HSCT in selected patients. Resistance mechanisms, particularly following venetoclax, remain a therapeutic challenge. These data support the continued use of gilteritinib beyond second-line and highlight the need for prospective studies to optimize sequencing strategies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Molica M, Miralles G, Dillon R, et al. Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients. Am J Hematol. 2025. PMID: 41273181. doi:10.1002/ajh.70142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。